Trial Profile
A multicenter randomized double-blind adaptive placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of house dust mite (Dermatophagoides pteronyssinus) in patients with allergic bronchial asthma and with allergic rhinitis or rhinoconjunctivitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2019
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Allergopharma
- 19 Oct 2019 Status changed from recruiting to completed.
- 13 Aug 2019 Planned number of patients changed from 446 to 1390.
- 29 Jul 2019 This trial has been completed in Croatia, according to European Clinical Trials Database.